HRP20090516T1 - Formulacija tienopiridinskog inhibitora agregacije trombocita - Google Patents

Formulacija tienopiridinskog inhibitora agregacije trombocita

Info

Publication number
HRP20090516T1
HRP20090516T1 HR20090516T HRP20090516T HRP20090516T1 HR P20090516 T1 HRP20090516 T1 HR P20090516T1 HR 20090516 T HR20090516 T HR 20090516T HR P20090516 T HRP20090516 T HR P20090516T HR P20090516 T1 HRP20090516 T1 HR P20090516T1
Authority
HR
Croatia
Prior art keywords
formulation
trimbocyt
thienopyridine
aggregation inhibitor
compound
Prior art date
Application number
HR20090516T
Other languages
English (en)
Croatian (hr)
Inventor
Brian Dziennik David
Beth Edelman Tamara
Lloyd Oren Peter
Louis Ternik Robert
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090516(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20090516T1 publication Critical patent/HRP20090516T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20090516T 2005-06-10 2006-06-06 Formulacija tienopiridinskog inhibitora agregacije trombocita HRP20090516T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10
PCT/US2006/021860 WO2006135605A2 (en) 2005-06-10 2006-06-06 Formulation of a thienopyridine platelet aggregation inhibitor

Publications (1)

Publication Number Publication Date
HRP20090516T1 true HRP20090516T1 (hr) 2009-10-31

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090516T HRP20090516T1 (hr) 2005-06-10 2006-06-06 Formulacija tienopiridinskog inhibitora agregacije trombocita

Country Status (34)

Country Link
US (1) US20080176893A1 (da)
EP (1) EP1896019B1 (da)
JP (1) JP2008543755A (da)
KR (2) KR20100076050A (da)
CN (1) CN101193633B (da)
AR (1) AR054283A1 (da)
AT (1) ATE441413T1 (da)
AU (1) AU2006258102B2 (da)
BR (1) BRPI0611350B8 (da)
CA (1) CA2611668C (da)
CY (1) CY1109502T1 (da)
DE (1) DE602006008942D1 (da)
DK (1) DK1896019T3 (da)
DO (1) DOP2006000126A (da)
EA (1) EA011693B1 (da)
EC (1) ECSP077984A (da)
ES (1) ES2330373T3 (da)
HR (1) HRP20090516T1 (da)
IL (1) IL187830A0 (da)
MA (1) MA29688B1 (da)
MX (1) MX2007015431A (da)
MY (1) MY151038A (da)
NO (1) NO20076317L (da)
NZ (1) NZ564003A (da)
PE (1) PE20070320A1 (da)
PL (1) PL1896019T3 (da)
PT (1) PT1896019E (da)
RS (1) RS51194B (da)
SI (1) SI1896019T1 (da)
TN (1) TNSN07466A1 (da)
TW (1) TWI318571B (da)
UA (1) UA91051C2 (da)
WO (1) WO2006135605A2 (da)
ZA (1) ZA200710697B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd PREPARATION WITH FILM COVER AND IMPROVED STABILITY
CN101568339A (zh) * 2006-12-07 2009-10-28 伊莱利利公司 普拉格雷的制品
TWI482641B (zh) * 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
US20100280064A1 (en) * 2006-12-07 2010-11-04 Tomoyuki Watanabe Pharmaceutical composition having improved storage stability
CA2672157C (en) * 2006-12-07 2016-07-26 Daiichi Sankyo Company, Limited Method for producing solid preparation
CA2672134C (en) * 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Solid medicinal preparation containing mannitol or lactose
CN101675058A (zh) * 2007-03-02 2010-03-17 第一三共株式会社 用于制备高纯度普拉格雷盐酸盐的方法
US8343995B2 (en) 2007-04-27 2013-01-01 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
US20110003847A1 (en) 2008-02-06 2011-01-06 Helm Ag Prasugrel Salts with Improved Properties
EP2107061A1 (en) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
ES2353853T3 (es) * 2008-04-25 2011-03-07 Sandoz Ag SAL HIDROGENOSULFATO DE 2-ACETOXI-5-("ALFA"-CICLOPROPILCARBONIL-2-FLUORBENCIL)-4,5,6,7-TETRAHIDROTIENO[3,2-c]PIRIDINA Y SU PREPARACIÓN.
SI2398468T1 (sl) * 2009-02-17 2017-03-31 Krka, D.D., Novo Mesto Farmacevtske sestave, ki obsegajo prasugrel ali njegove farmacevtsko sprejemljive kislinske adicijske soli in postopek za njihovo pripravo
CN102625658B (zh) 2009-05-13 2015-01-28 锡德克斯药物公司 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060560A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
EP2722037A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Prasugrel formulations
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
PL208386B1 (pl) * 2000-07-06 2011-04-29 Daiichi Sankyo Company Sole addycyjne 2-acetoksy-5-(α-cyklopropylokarbonylo-2-flurobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, lekarstwo zawierające jako składnik czynny te sole, zastosowanie soli, sposoby wytwarzania soli addycyjnych 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, sposób wytwarzania chlorowodorku 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
PL1653930T3 (pl) * 2003-08-05 2008-06-30 Zentiva Ks Sposoby stabilizacji atorwastatyny

Also Published As

Publication number Publication date
AU2006258102A1 (en) 2006-12-21
BRPI0611350B8 (pt) 2021-05-25
NZ564003A (en) 2011-07-29
BRPI0611350B1 (pt) 2020-09-15
AR054283A1 (es) 2007-06-13
CA2611668C (en) 2013-10-15
CY1109502T1 (el) 2014-08-13
UA91051C2 (ru) 2010-06-25
AU2006258102B2 (en) 2011-09-15
MX2007015431A (es) 2008-02-21
NO20076317L (no) 2008-02-29
HK1116422A1 (en) 2008-12-24
BRPI0611350A2 (pt) 2010-12-07
EP1896019B1 (en) 2009-09-02
CN101193633B (zh) 2011-12-14
SI1896019T1 (sl) 2010-01-29
TNSN07466A1 (en) 2009-03-17
DOP2006000126A (es) 2006-12-15
ES2330373T3 (es) 2009-12-09
EA200702670A1 (ru) 2008-04-28
KR20080008413A (ko) 2008-01-23
CA2611668A1 (en) 2006-12-21
EA011693B1 (ru) 2009-04-28
WO2006135605A2 (en) 2006-12-21
ATE441413T1 (de) 2009-09-15
ECSP077984A (es) 2008-01-23
DK1896019T3 (da) 2009-10-26
JP2008543755A (ja) 2008-12-04
TWI318571B (en) 2009-12-21
ZA200710697B (en) 2009-08-26
CN101193633A (zh) 2008-06-04
RS51194B (sr) 2010-10-31
MY151038A (en) 2014-03-31
MA29688B1 (fr) 2008-08-01
US20080176893A1 (en) 2008-07-24
PT1896019E (pt) 2009-11-19
PL1896019T3 (pl) 2010-01-29
IL187830A0 (en) 2008-04-13
TW200718420A (en) 2007-05-16
PE20070320A1 (es) 2007-05-12
WO2006135605A3 (en) 2007-04-12
DE602006008942D1 (en) 2009-10-15
KR20100076050A (ko) 2010-07-05
EP1896019A2 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
MY151038A (en) Formulation of a thienopyridine platlet aggregation inhibitor
EP3586631A3 (en) Plant health composition
DK1848659T3 (da) Oxygenopfangningssammensætninger og emballage omfattende sammensætningerne
EA200801859A1 (ru) Неводная композиция стабильного витамина "c", способ ее приготовления и применения
CL2012000887A1 (es) Mezcla fungicida sinergica que comprende fluorocitosina y otros compuestos fungicos; composicion fungicida que comprende dicha mezcla y un adyuvante agricolamente aceptable o portador.
UA91482C2 (ru) Агрохимическая композиция с фунгицидным действием и ее применение
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
MX382264B (es) Composiciones que comprenden amlodipina y bisoprolol.
UY30543A1 (es) Formulacion de aerosol para la inhalacion de beta- agonistas
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
DE60333746D1 (de) Thienylverbindungen
WO2008049042A3 (en) Ophthalmic compositions containing diglycine
ZA200608416B (en) Herbicidal composition
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
UY29844A1 (es) Formulación en aerosol para la inhalación de beta-agonistas
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
CR10690A (es) Nuevos derivados de fluoreno, composiciones que los contienen y utilizacion como inhibidores de la proteina chaperona hsp90
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
CA2659937A1 (en) Antimicrobial composition useful for preserving wood
AR046254A1 (es) Productos farmaceuticos estables
MA31678B1 (fr) Composition therapeutique aromatisee a base d'argile
FR2893924B1 (fr) Paquet d'articles comprenant un flanc le recouvrant partiellement et un film enveloppant le tout.
SG163490A1 (en) Packaging body
SV2006002238A (es) Inhibidores de la adenilato ciclasa soluble ref. p-sv-78. 959/gh
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases